Stem definition | Drug id | CAS RN |
---|---|---|
751 | 303-53-7 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 200 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.37 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 55 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 26, 1977 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 1045.70 | 10.55 | 1164 | 66058 | 144756 | 46474084 |
Drug abuse | 429.19 | 10.55 | 492 | 66730 | 62916 | 46555924 |
Toxicity to various agents | 428.51 | 10.55 | 942 | 66280 | 210824 | 46408016 |
Respiratory arrest | 236.42 | 10.55 | 267 | 66955 | 33549 | 46585291 |
Temperature regulation disorder | 216.91 | 10.55 | 103 | 67119 | 3257 | 46615583 |
Food allergy | 154.49 | 10.55 | 106 | 67116 | 6827 | 46612013 |
Cardio-respiratory arrest | 152.00 | 10.55 | 293 | 66929 | 59576 | 46559264 |
Coeliac disease | 149.06 | 10.55 | 105 | 67117 | 7056 | 46611784 |
Sedation complication | 140.50 | 10.55 | 79 | 67143 | 3566 | 46615274 |
Immunodeficiency | 128.40 | 10.55 | 124 | 67098 | 12982 | 46605858 |
Pain | 123.00 | 10.55 | 1134 | 66088 | 475814 | 46143026 |
Bursitis | 114.36 | 10.55 | 142 | 67080 | 19700 | 46599140 |
Drug hypersensitivity | 109.04 | 10.55 | 661 | 66561 | 243164 | 46375676 |
Cardiac arrest | 106.53 | 10.55 | 329 | 66893 | 90070 | 46528770 |
Sedation | 105.75 | 10.55 | 147 | 67075 | 22763 | 46596077 |
Back pain | 104.65 | 10.55 | 586 | 66636 | 209453 | 46409387 |
Constipation | 101.98 | 10.55 | 508 | 66714 | 173589 | 46445251 |
Poisoning | 93.53 | 10.55 | 108 | 67114 | 13886 | 46604954 |
Intentional product misuse | 89.64 | 10.55 | 205 | 67017 | 46923 | 46571917 |
Hyperhidrosis | 88.98 | 10.55 | 307 | 66915 | 89001 | 46529839 |
Creatinine renal clearance decreased | 88.41 | 10.55 | 76 | 67146 | 6844 | 46611996 |
Fibromyalgia | 75.39 | 10.55 | 164 | 67058 | 36299 | 46582541 |
Maternal exposure during pregnancy | 74.89 | 10.55 | 27 | 67195 | 102522 | 46516318 |
Cognitive disorder | 74.12 | 10.55 | 164 | 67058 | 36719 | 46582121 |
Exposure during pregnancy | 73.27 | 10.55 | 32 | 67190 | 108180 | 46510660 |
Decorticate posture | 68.57 | 10.55 | 24 | 67198 | 336 | 46618504 |
Thrombocytopenia | 67.72 | 10.55 | 50 | 67172 | 126531 | 46492309 |
Hyponatraemia | 65.45 | 10.55 | 32 | 67190 | 101300 | 46517540 |
Orthostatic hypotension | 60.48 | 10.55 | 119 | 67103 | 24539 | 46594301 |
Fluid retention | 57.52 | 10.55 | 183 | 67039 | 50863 | 46567977 |
Leukopenia | 55.24 | 10.55 | 15 | 67207 | 68328 | 46550512 |
Febrile neutropenia | 55.13 | 10.55 | 34 | 67188 | 94593 | 46524247 |
Upper respiratory tract infection | 54.40 | 10.55 | 208 | 67014 | 63348 | 46555492 |
Anxiety | 52.98 | 10.55 | 445 | 66777 | 181512 | 46437328 |
Neutropenia | 52.49 | 10.55 | 78 | 67144 | 143126 | 46475714 |
Muscle spasms | 50.04 | 10.55 | 326 | 66896 | 122787 | 46496053 |
Blood calcium decreased | 49.00 | 10.55 | 84 | 67138 | 15589 | 46603251 |
Balance disorder | 47.89 | 10.55 | 202 | 67020 | 64319 | 46554521 |
Migraine | 47.22 | 10.55 | 213 | 67009 | 69813 | 46549027 |
Cardiac failure | 46.19 | 10.55 | 29 | 67193 | 79919 | 46538921 |
Headache | 44.76 | 10.55 | 950 | 66272 | 477402 | 46141438 |
Drug interaction | 44.48 | 10.55 | 147 | 67075 | 202947 | 46415893 |
Product dose omission issue | 44.29 | 10.55 | 403 | 66819 | 168117 | 46450723 |
Pancytopenia | 42.45 | 10.55 | 36 | 67186 | 85022 | 46533818 |
Rash erythematous | 42.27 | 10.55 | 127 | 67095 | 34223 | 46584617 |
Myocardial depression | 40.39 | 10.55 | 18 | 67204 | 490 | 46618350 |
Acute kidney injury | 40.01 | 10.55 | 189 | 67033 | 235666 | 46383174 |
Anaemia | 38.84 | 10.55 | 213 | 67009 | 255566 | 46363274 |
Synovitis | 35.49 | 10.55 | 22 | 67200 | 61053 | 46557787 |
Spinal operation | 34.10 | 10.55 | 41 | 67181 | 5499 | 46613341 |
Depression | 33.75 | 10.55 | 384 | 66838 | 169720 | 46449120 |
Malignant neoplasm progression | 32.99 | 10.55 | 27 | 67195 | 64899 | 46553941 |
Lactic acidosis | 32.45 | 10.55 | 5 | 67217 | 33904 | 46584936 |
Pulmonary malformation | 32.07 | 10.55 | 10 | 67212 | 95 | 46618745 |
Injury | 32.01 | 10.55 | 137 | 67085 | 43890 | 46574950 |
Hepatocellular injury | 31.57 | 10.55 | 3 | 67219 | 29519 | 46589321 |
C-reactive protein increased | 31.50 | 10.55 | 23 | 67199 | 58567 | 46560273 |
Hyperkalaemia | 31.26 | 10.55 | 17 | 67205 | 50692 | 46568148 |
Glossodynia | 30.21 | 10.55 | 13 | 67209 | 44360 | 46574480 |
Asthma | 29.93 | 10.55 | 230 | 66992 | 91312 | 46527528 |
Systemic lupus erythematosus | 29.67 | 10.55 | 30 | 67192 | 65150 | 46553690 |
Suspected suicide | 29.52 | 10.55 | 35 | 67187 | 4626 | 46614214 |
Pyrexia | 29.40 | 10.55 | 341 | 66881 | 348461 | 46270379 |
Drug ineffective | 28.84 | 10.55 | 750 | 66472 | 677088 | 45941752 |
Exposure via ingestion | 28.80 | 10.55 | 30 | 67192 | 3437 | 46615403 |
Fall | 28.27 | 10.55 | 646 | 66576 | 328451 | 46290389 |
Renal impairment | 27.73 | 10.55 | 40 | 67182 | 74332 | 46544508 |
Pleural effusion | 27.72 | 10.55 | 48 | 67174 | 82904 | 46535936 |
Gamma-glutamyltransferase increased | 27.53 | 10.55 | 6 | 67216 | 31734 | 46587106 |
Lower respiratory tract infection | 26.65 | 10.55 | 24 | 67198 | 55065 | 46563775 |
Respiratory tract malformation | 26.14 | 10.55 | 8 | 67214 | 71 | 46618769 |
Respiratory depression | 26.08 | 10.55 | 54 | 67168 | 11546 | 46607294 |
Urinary incontinence | 25.75 | 10.55 | 95 | 67127 | 28435 | 46590405 |
Sinusitis | 25.75 | 10.55 | 293 | 66929 | 129475 | 46489365 |
Memory impairment | 25.66 | 10.55 | 195 | 67027 | 77142 | 46541698 |
Intervertebral disc protrusion | 25.63 | 10.55 | 76 | 67146 | 20329 | 46598511 |
Alanine aminotransferase increased | 25.38 | 10.55 | 56 | 67166 | 88395 | 46530445 |
Electrocardiogram QRS complex prolonged | 25.19 | 10.55 | 35 | 67187 | 5414 | 46613426 |
Depressed level of consciousness | 25.13 | 10.55 | 135 | 67087 | 47434 | 46571406 |
Bone marrow failure | 24.95 | 10.55 | 6 | 67216 | 29663 | 46589177 |
Electrocardiogram QT prolonged | 24.07 | 10.55 | 23 | 67199 | 51302 | 46567538 |
Therapy interrupted | 23.98 | 10.55 | 50 | 67172 | 10741 | 46608099 |
Dysphoria | 23.53 | 10.55 | 31 | 67191 | 4558 | 46614282 |
Therapy cessation | 23.47 | 10.55 | 88 | 67134 | 26541 | 46592299 |
Mobility decreased | 23.11 | 10.55 | 158 | 67064 | 60436 | 46558404 |
Blood creatinine increased | 23.07 | 10.55 | 47 | 67175 | 76356 | 46542484 |
Lung cyst | 23.05 | 10.55 | 8 | 67214 | 109 | 46618731 |
Neck pain | 22.78 | 10.55 | 147 | 67075 | 55159 | 46563681 |
Hypokalaemia | 22.67 | 10.55 | 59 | 67163 | 87965 | 46530875 |
Insomnia | 22.55 | 10.55 | 348 | 66874 | 164576 | 46454264 |
Gluten sensitivity | 22.44 | 10.55 | 12 | 67210 | 490 | 46618350 |
Device expulsion | 22.33 | 10.55 | 6 | 67216 | 27536 | 46591304 |
Off label use | 22.26 | 10.55 | 399 | 66823 | 379442 | 46239398 |
Fracture pain | 22.23 | 10.55 | 11 | 67211 | 381 | 46618459 |
Hand deformity | 22.19 | 10.55 | 11 | 67211 | 34563 | 46584277 |
International normalised ratio increased | 22 | 10.55 | 21 | 67201 | 46862 | 46571978 |
Unresponsive to stimuli | 21.77 | 10.55 | 98 | 67124 | 32076 | 46586764 |
Decreased appetite | 21.57 | 10.55 | 177 | 67045 | 193659 | 46425181 |
Cholestasis | 21.54 | 10.55 | 6 | 67216 | 26887 | 46591953 |
Overdose | 21.47 | 10.55 | 233 | 66989 | 101746 | 46517094 |
Serum sickness-like reaction | 21.44 | 10.55 | 11 | 67211 | 412 | 46618428 |
Abortion spontaneous | 21.13 | 10.55 | 19 | 67203 | 43627 | 46575213 |
Interstitial lung disease | 21.13 | 10.55 | 28 | 67194 | 53921 | 46564919 |
Back disorder | 21.08 | 10.55 | 43 | 67179 | 9098 | 46609742 |
Jaundice | 20.37 | 10.55 | 8 | 67214 | 28837 | 46590003 |
Aspartate aminotransferase increased | 20.07 | 10.55 | 53 | 67169 | 78647 | 46540193 |
Mucosal inflammation | 20.05 | 10.55 | 16 | 67206 | 38960 | 46579880 |
Bronchitis | 19.99 | 10.55 | 237 | 66985 | 105742 | 46513098 |
Peritonitis | 19.94 | 10.55 | 3 | 67219 | 20711 | 46598129 |
Blood lactate dehydrogenase increased | 19.66 | 10.55 | 3 | 67219 | 20497 | 46598343 |
Dry mouth | 19.64 | 10.55 | 141 | 67081 | 54785 | 46564055 |
Drug screen positive | 19.51 | 10.55 | 26 | 67196 | 3865 | 46614975 |
Atrial fibrillation | 19.36 | 10.55 | 80 | 67142 | 103510 | 46515330 |
Post-traumatic neck syndrome | 19.35 | 10.55 | 16 | 67206 | 1365 | 46617475 |
Angioedema | 19.20 | 10.55 | 17 | 67205 | 39325 | 46579515 |
Sepsis | 19.14 | 10.55 | 116 | 67106 | 135898 | 46482942 |
Road traffic accident | 19.01 | 10.55 | 76 | 67146 | 23615 | 46595225 |
Blood bilirubin increased | 18.92 | 10.55 | 13 | 67209 | 34171 | 46584669 |
Pre-existing condition improved | 18.80 | 10.55 | 34 | 67188 | 6578 | 46612262 |
Meniscus injury | 18.56 | 10.55 | 32 | 67190 | 5964 | 46612876 |
Liver disorder | 18.29 | 10.55 | 16 | 67206 | 37230 | 46581610 |
Blood alkaline phosphatase increased | 18.29 | 10.55 | 18 | 67204 | 39591 | 46579249 |
Emotional distress | 18.20 | 10.55 | 90 | 67132 | 30617 | 46588223 |
Infrequent bowel movements | 18.00 | 10.55 | 14 | 67208 | 1094 | 46617746 |
Drug-induced liver injury | 17.97 | 10.55 | 7 | 67215 | 25361 | 46593479 |
Anti-cyclic citrullinated peptide antibody positive | 17.92 | 10.55 | 3 | 67219 | 19142 | 46599698 |
Hepatic function abnormal | 17.87 | 10.55 | 14 | 67208 | 34407 | 46584433 |
Agranulocytosis | 17.68 | 10.55 | 5 | 67217 | 22180 | 46596660 |
Ascites | 17.62 | 10.55 | 16 | 67206 | 36568 | 46582272 |
Anticholinergic syndrome | 17.52 | 10.55 | 17 | 67205 | 1789 | 46617051 |
Altered state of consciousness | 17.28 | 10.55 | 6 | 67216 | 23342 | 46595498 |
Intervertebral disc degeneration | 17.25 | 10.55 | 50 | 67172 | 13202 | 46605638 |
Stevens-Johnson syndrome | 17.22 | 10.55 | 6 | 67216 | 23291 | 46595549 |
Fatigue | 17.12 | 10.55 | 1054 | 66168 | 607643 | 46011197 |
Psoriatic arthropathy | 17.06 | 10.55 | 100 | 67122 | 36279 | 46582561 |
Surgery | 16.80 | 10.55 | 84 | 67138 | 28701 | 46590139 |
Hypoaesthesia | 16.69 | 10.55 | 252 | 66970 | 118617 | 46500223 |
General physical health deterioration | 16.67 | 10.55 | 98 | 67124 | 115671 | 46503169 |
Back injury | 16.48 | 10.55 | 33 | 67189 | 6888 | 46611952 |
Liver function test abnormal | 16.36 | 10.55 | 26 | 67196 | 46461 | 46572379 |
Hypoglycaemia | 15.93 | 10.55 | 34 | 67188 | 54315 | 46564525 |
Cardiac failure congestive | 15.83 | 10.55 | 73 | 67149 | 91677 | 46527163 |
Psoriasis | 15.81 | 10.55 | 178 | 67044 | 78426 | 46540414 |
Disseminated intravascular coagulation | 15.68 | 10.55 | 4 | 67218 | 19001 | 46599839 |
Lymphatic system neoplasm | 15.63 | 10.55 | 5 | 67217 | 52 | 46618788 |
Gastrointestinal haemorrhage | 15.57 | 10.55 | 58 | 67164 | 77315 | 46541525 |
Uterine perforation | 15.37 | 10.55 | 33 | 67189 | 7234 | 46611606 |
Circulatory collapse | 15.26 | 10.55 | 6 | 67216 | 21618 | 46597222 |
Withdrawal syndrome | 15.22 | 10.55 | 59 | 67163 | 18075 | 46600765 |
Weight increased | 15.07 | 10.55 | 326 | 66896 | 164147 | 46454693 |
Lower limb fracture | 14.46 | 10.55 | 45 | 67177 | 12353 | 46606487 |
Muscle strain | 14.37 | 10.55 | 31 | 67191 | 6818 | 46612022 |
Platelet count decreased | 14.23 | 10.55 | 85 | 67137 | 99939 | 46518901 |
Cholecystitis chronic | 14.04 | 10.55 | 40 | 67182 | 10459 | 46608381 |
Spleen congestion | 13.83 | 10.55 | 6 | 67216 | 153 | 46618687 |
Neutrophil count decreased | 13.72 | 10.55 | 26 | 67196 | 43400 | 46575440 |
Melaena | 13.55 | 10.55 | 12 | 67210 | 27760 | 46591080 |
Transaminases increased | 13.54 | 10.55 | 12 | 67210 | 27749 | 46591091 |
Dyspnoea | 13.50 | 10.55 | 606 | 66616 | 514942 | 46103898 |
Pericarditis | 13.38 | 10.55 | 9 | 67213 | 23918 | 46594922 |
Drug eruption | 13.36 | 10.55 | 7 | 67215 | 21322 | 46597518 |
Somnolence | 13.32 | 10.55 | 307 | 66915 | 156214 | 46462626 |
Irritability | 13.21 | 10.55 | 79 | 67143 | 28867 | 46589973 |
Epilepsy | 13.18 | 10.55 | 9 | 67213 | 23729 | 46595111 |
Exposure via inhalation | 13.12 | 10.55 | 4 | 67218 | 35 | 46618805 |
Disease progression | 12.77 | 10.55 | 78 | 67144 | 91222 | 46527618 |
Premature delivery | 12.75 | 10.55 | 8 | 67214 | 22061 | 46596779 |
Drug withdrawal syndrome | 12.66 | 10.55 | 75 | 67147 | 27309 | 46591531 |
Drug intolerance | 12.64 | 10.55 | 143 | 67079 | 146906 | 46471934 |
Hyperaesthesia | 12.59 | 10.55 | 32 | 67190 | 7824 | 46611016 |
Joint range of motion decreased | 12.52 | 10.55 | 49 | 67173 | 15075 | 46603765 |
Cardiogenic shock | 12.50 | 10.55 | 4 | 67218 | 16380 | 46602460 |
Rash maculo-papular | 12.49 | 10.55 | 13 | 67209 | 27861 | 46590979 |
Poor venous access | 12.45 | 10.55 | 33 | 67189 | 8275 | 46610565 |
Poor quality sleep | 12.29 | 10.55 | 49 | 67173 | 15204 | 46603636 |
Haematemesis | 12.28 | 10.55 | 14 | 67208 | 28792 | 46590048 |
Muscle neoplasm | 11.99 | 10.55 | 4 | 67218 | 48 | 46618792 |
Feeling abnormal | 11.81 | 10.55 | 249 | 66973 | 124811 | 46494029 |
Copper deficiency | 11.77 | 10.55 | 4 | 67218 | 51 | 46618789 |
Gallbladder neoplasm | 11.77 | 10.55 | 4 | 67218 | 51 | 46618789 |
Concussion | 11.72 | 10.55 | 29 | 67193 | 6974 | 46611866 |
Hostility | 11.70 | 10.55 | 12 | 67210 | 1350 | 46617490 |
Antibody test positive | 11.68 | 10.55 | 15 | 67207 | 2150 | 46616690 |
Multiple organ dysfunction syndrome | 11.59 | 10.55 | 37 | 67185 | 51673 | 46567167 |
Cerebral infarction | 11.52 | 10.55 | 10 | 67212 | 23356 | 46595484 |
Spinal cord neoplasm | 11.47 | 10.55 | 6 | 67216 | 234 | 46618606 |
Bradycardia | 11.29 | 10.55 | 53 | 67169 | 66245 | 46552595 |
Oedema peripheral | 11.24 | 10.55 | 162 | 67060 | 159544 | 46459296 |
Upper gastrointestinal haemorrhage | 11.24 | 10.55 | 5 | 67217 | 16733 | 46602107 |
Lymphopenia | 11.20 | 10.55 | 4 | 67218 | 15289 | 46603551 |
Tenderness | 11.11 | 10.55 | 51 | 67171 | 16830 | 46602010 |
Sleep apnoea syndrome | 11.05 | 10.55 | 62 | 67160 | 22139 | 46596701 |
Neck surgery | 10.96 | 10.55 | 12 | 67210 | 1455 | 46617385 |
Libido increased | 10.94 | 10.55 | 9 | 67213 | 763 | 46618077 |
Treatment failure | 10.80 | 10.55 | 84 | 67138 | 93003 | 46525837 |
Ischaemic hepatitis | 10.73 | 10.55 | 14 | 67208 | 2039 | 46616801 |
Pregnancy | 10.71 | 10.55 | 14 | 67208 | 27123 | 46591717 |
Alopecia | 10.66 | 10.55 | 167 | 67055 | 162247 | 46456593 |
Body height increased | 10.61 | 10.55 | 4 | 67218 | 70 | 46618770 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Completed suicide | 500.38 | 12.41 | 475 | 21019 | 99017 | 29831967 |
Drug abuse | 251.95 | 12.41 | 302 | 21192 | 81770 | 29849214 |
Toxicity to various agents | 229.43 | 12.41 | 435 | 21059 | 176748 | 29754236 |
Respiratory arrest | 143.16 | 12.41 | 138 | 21356 | 29120 | 29901864 |
Intentional product misuse | 68.36 | 12.41 | 103 | 21391 | 34564 | 29896420 |
Overdose | 58.27 | 12.41 | 162 | 21332 | 84175 | 29846809 |
Milk-alkali syndrome | 55.39 | 12.41 | 19 | 21475 | 520 | 29930464 |
Cardio-respiratory arrest | 53.04 | 12.41 | 123 | 21371 | 57183 | 29873801 |
Cardiac arrest | 46.12 | 12.41 | 159 | 21335 | 92691 | 29838293 |
Back pain | 45.26 | 12.41 | 169 | 21325 | 102427 | 29828557 |
Back disorder | 38.56 | 12.41 | 33 | 21461 | 5961 | 29925023 |
General physical health deterioration | 38.35 | 12.41 | 12 | 21482 | 99932 | 29831052 |
Product dose omission issue | 36.37 | 12.41 | 146 | 21348 | 91485 | 29839499 |
Serotonin syndrome | 33.61 | 12.41 | 52 | 21442 | 17839 | 29913145 |
Lymphocyte count abnormal | 31.78 | 12.41 | 13 | 21481 | 585 | 29930399 |
Spinal operation | 31.58 | 12.41 | 20 | 21474 | 2276 | 29928708 |
Interstitial lung disease | 29.72 | 12.41 | 4 | 21490 | 60193 | 29870791 |
Pain | 28.16 | 12.41 | 216 | 21278 | 172425 | 29758559 |
Back injury | 28.01 | 12.41 | 22 | 21472 | 3523 | 29927461 |
Poisoning | 25.59 | 12.41 | 36 | 21458 | 11346 | 29919638 |
Leukopenia | 24.89 | 12.41 | 5 | 21489 | 56154 | 29874830 |
Accidental overdose | 24.87 | 12.41 | 46 | 21448 | 18229 | 29912755 |
Cardiac failure | 24.15 | 12.41 | 15 | 21479 | 83403 | 29847581 |
Thrombocytopenia | 23.35 | 12.41 | 39 | 21455 | 137005 | 29793979 |
Drug hypersensitivity | 23.15 | 12.41 | 104 | 21390 | 68415 | 29862569 |
Anaemia | 22.77 | 12.41 | 75 | 21419 | 207917 | 29723067 |
Muscle spasms | 21.59 | 12.41 | 98 | 21396 | 64740 | 29866244 |
Suspected suicide | 21.56 | 12.41 | 18 | 21476 | 3143 | 29927841 |
C-reactive protein increased | 21.19 | 12.41 | 3 | 21491 | 43470 | 29887514 |
Anion gap | 21.18 | 12.41 | 10 | 21484 | 636 | 29930348 |
Spinal fracture | 20.89 | 12.41 | 25 | 21469 | 6723 | 29924261 |
Exposure via ingestion | 20.19 | 12.41 | 16 | 21478 | 2595 | 29928389 |
Neck pain | 19.40 | 12.41 | 45 | 21449 | 20899 | 29910085 |
Death | 19.18 | 12.41 | 361 | 21133 | 356922 | 29574062 |
Irritable bowel syndrome | 18.47 | 12.41 | 16 | 21478 | 2936 | 29928048 |
Hyponatraemia | 18.21 | 12.41 | 13 | 21481 | 67189 | 29863795 |
Vasoplegia syndrome | 17.30 | 12.41 | 11 | 21483 | 1260 | 29929724 |
Pain in extremity | 16.88 | 12.41 | 136 | 21358 | 110085 | 29820899 |
Arthralgia | 16.38 | 12.41 | 159 | 21335 | 135632 | 29795352 |
Feeling abnormal | 16.15 | 12.41 | 82 | 21412 | 56674 | 29874310 |
Ankylosing spondylitis | 16.05 | 12.41 | 18 | 21476 | 4516 | 29926468 |
Malignant neoplasm progression | 14.85 | 12.41 | 18 | 21476 | 72269 | 29858715 |
Insomnia | 14.74 | 12.41 | 116 | 21378 | 93220 | 29837764 |
Blood creatinine increased | 14.65 | 12.41 | 27 | 21467 | 91348 | 29839636 |
Anion gap abnormal | 14.57 | 12.41 | 5 | 21489 | 137 | 29930847 |
Metabolic alkalosis | 14.49 | 12.41 | 10 | 21484 | 1314 | 29929670 |
Product use in unapproved indication | 14.46 | 12.41 | 19 | 21475 | 73674 | 29857310 |
Hepatic function abnormal | 14.44 | 12.41 | 6 | 21488 | 41939 | 29889045 |
Respiratory failure | 14.21 | 12.41 | 32 | 21462 | 100610 | 29830374 |
Musculoskeletal stiffness | 14.07 | 12.41 | 57 | 21437 | 35824 | 29895160 |
Red blood cell sedimentation rate abnormal | 13.99 | 12.41 | 11 | 21483 | 1764 | 29929220 |
Peripheral swelling | 13.87 | 12.41 | 83 | 21411 | 60991 | 29869993 |
Pyrexia | 13.80 | 12.41 | 140 | 21354 | 294349 | 29636635 |
Painful ejaculation | 13.79 | 12.41 | 4 | 21490 | 62 | 29930922 |
Unresponsive to stimuli | 13.75 | 12.41 | 46 | 21448 | 26373 | 29904611 |
Priapism | 13.75 | 12.41 | 17 | 21477 | 4726 | 29926258 |
Prescribed overdose | 13.51 | 12.41 | 23 | 21471 | 8538 | 29922446 |
Contusion | 13.32 | 12.41 | 51 | 21443 | 31229 | 29899755 |
Respiratory depression | 13.26 | 12.41 | 27 | 21467 | 11476 | 29919508 |
Ascites | 12.59 | 12.41 | 5 | 21489 | 35916 | 29895068 |
Renal impairment | 12.52 | 12.41 | 26 | 21468 | 84158 | 29846826 |
Gastrooesophageal reflux disease | 12.45 | 12.41 | 51 | 21443 | 32204 | 29898780 |
Source | Code | Description |
---|---|---|
ATC | M03BX08 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Other centrally acting agents |
FDA PE | N0000175730 | Centrally-mediated Muscle Relaxation |
FDA EPC | N0000175737 | Muscle Relaxant |
CHEBI has role | CHEBI:35469 | thymoanaleptics |
CHEBI has role | CHEBI:35473 | tranquilising drug |
CHEBI has role | CHEBI:51371 | muscle relaxants |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D000929 | Antidepressive Agents, Tricyclic |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D009125 | Muscle Relaxants, Central |
MeSH PA | D009465 | Neuromuscular Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Spasticity | indication | 221360009 | |
Fibromyalgia | off-label use | 203082005 | DOID:631 |
Sinus tachycardia | contraindication | 11092001 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic heart failure | contraindication | 48447003 | |
Hepatic failure | contraindication | 59927004 | |
Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
Heart block | contraindication | 233916004 | |
Retention of urine | contraindication | 267064002 | |
Myocardial infarction in recovery phase | contraindication | 418044006 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.66 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 7.54 | WOMBAT-PK | CHEMBL | |||
5-hydroxytryptamine receptor 2C | GPCR | ANTAGONIST | Ki | 7.24 | WOMBAT-PK | ||||
Aldehyde oxidase | Enzyme | IC50 | 5.51 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 6.95 | WOMBAT-PK | |||||
Histamine H1 receptor | GPCR | Ki | 8.83 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 7 | GPCR | Ki | 6.82 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.84 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.81 | WOMBAT-PK | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 7.44 | WOMBAT-PK | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.97 | WOMBAT-PK | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 4.73 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.22 | PDSP | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 8.22 | PDSP | |||||
Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | IC50 | 6.52 | CHEMBL |
ID | Source |
---|---|
4019699 | VUID |
N0000147791 | NUI |
D00772 | KEGG_DRUG |
6202-23-9 | SECONDARY_CAS_RN |
4017956 | VANDF |
4019699 | VANDF |
C0056732 | UMLSCUI |
CHEBI:3996 | CHEBI |
CHEMBL669 | ChEMBL_ID |
CHEMBL1200636 | ChEMBL_ID |
DB00924 | DRUGBANK_ID |
C004704 | MESH_SUPPLEMENTAL_RECORD_UI |
2895 | PUBCHEM_CID |
7152 | IUPHAR_LIGAND_ID |
791 | INN_ID |
69O5WQQ5TI | UNII |
21949 | RXNORM |
217 | MMSL |
4517 | MMSL |
d00963 | MMSL |
001678 | NDDF |
004680 | NDDF |
373779004 | SNOMEDCT_US |
63083007 | SNOMEDCT_US |
80802008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1920 | CAPSULE, EXTENDED RELEASE | 15 mg | ORAL | NDA AUTHORIZED GENERIC | 30 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1921 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | NDA AUTHORIZED GENERIC | 30 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1436 | CAPSULE, EXTENDED RELEASE | 15 mg | ORAL | NDA AUTHORIZED GENERIC | 28 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1437 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | NDA AUTHORIZED GENERIC | 28 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1350 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 20 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-7350 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 19 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3256 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 20 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-3330 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 20 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5658 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 20 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8084 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 21 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8182 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 14 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7809 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 20 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-072 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 23 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-159 | TABLET | 10 mg | ORAL | ANDA | 13 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-200 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 13 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-006 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 13 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-007 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 13 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 12634-528 | TABLET | 10 mg | ORAL | ANDA | 20 sections |
Cyclobenzaprine Hydrochloride | Human Prescription Drug Label | 1 | 16571-782 | TABLET, FILM COATED | 5 mg | ORAL | ANDA | 23 sections |
Cyclobenzaprine Hydrochloride | Human Prescription Drug Label | 1 | 16571-783 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 23 sections |
CYCLOBENZAPRINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-065 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
CYCLOBENZAPRINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-544 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
Amrix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-596 | CAPSULE, EXTENDED RELEASE | 15 mg | ORAL | NDA | 13 sections |
FEXMID | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-699 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 22 sections |
Amrix | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-810 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | NDA | 13 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-036 | TABLET | 5 mg | ORAL | ANDA | 13 sections |
Cyclobenzaprine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-037 | TABLET | 10 mg | ORAL | ANDA | 13 sections |
AMRIX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-723 | CAPSULE, EXTENDED RELEASE | 15 mg | ORAL | NDA | 22 sections |
Fexmid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-830 | TABLET, FILM COATED | 7.50 mg | ORAL | ANDA | 22 sections |
AMRIX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-953 | CAPSULE, EXTENDED RELEASE | 30 mg | ORAL | NDA | 22 sections |